US 10,889,621 B2
Compositions and methods for treating conditions related to ephrin signaling with Cupredoxins
Ananda Chakrabarty, Villa Park, IL (US); Tapas Das Gupta, River Forest, IL (US); Tohru Yamada, Oak Park, IL (US); Anita Chaudhari, Clifton Park, NY (US); Arsenio Fialho, Lisbon (PT); and Yonghua Zhu, Chicago, IL (US)
Assigned to THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US)
Filed by The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed on Apr. 26, 2018, as Appl. No. 15/963,605.
Application 15/963,605 is a division of application No. 12/130,705, filed on May 30, 2008, granted, now 9,957,304.
Application 12/130,705 is a division of application No. 11/436,592, filed on May 19, 2006, granted, now 7,381,701, issued on Jun. 3, 2008.
Application 11/436,592 is a continuation in part of application No. 11/244,105, filed on Oct. 6, 2005, granted, now 7,691,383, issued on Apr. 6, 2010.
Application 12/130,705 is a continuation in part of application No. 10/720,603, filed on Nov. 24, 2003, granted, now 7,491,394, issued on Feb. 17, 2009.
Application 10/720,603 is a continuation in part of application No. 10/047,710, filed on Jan. 15, 2002, granted, now 7,084,105, issued on Aug. 1, 2006.
Claims priority of provisional application 60/764,749, filed on Feb. 3, 2006.
Claims priority of provisional application 60/682,812, filed on May 20, 2005.
Claims priority of provisional application 60/616,782, filed on Oct. 7, 2004.
Claims priority of provisional application 60/680,500, filed on May 13, 2005.
Claims priority of provisional application 60/414,550, filed on Aug. 15, 2003.
Claims priority of provisional application 60/269,133, filed on Feb. 15, 2001.
Prior Publication US 2018/0319847 A1, Nov. 8, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/21 (2006.01); A61K 38/16 (2006.01); C07K 14/195 (2006.01); C07K 14/705 (2006.01)
CPC C07K 14/21 (2013.01) [A61K 38/164 (2013.01); A61K 38/168 (2013.01); C07K 14/195 (2013.01); C07K 14/705 (2013.01)] 13 Claims
 
1. A method comprising administration of a composition comprising:
an amino acid sequence that binds to either an ephrin or an Eph receptor and has been modified, the amino acid sequence is a truncation of cupredoxin consisting of a sequence selected from the group consisting of: SEQ ID NO: 18, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 34, and
the modification is selected from the group consisting of: glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation, ADP-ribosylation, amidation, acetylation, polyethylene glycol (PEG) modification, and phosphorylation; and
a pharmaceutically acceptable carrier.